U.S. Sleep Apnea Implants Market - By Product, By Indication, By End Use - Forecast, 2025 - 2034

U.S. Sleep Apnea Implants Market Size

The U.S. sleep apnea implants market was valued at USD 840 million in 2024 and is expected to exhibit growth at a CAGR of 17.4% from 2025 to 2034. High market growth can be attributed to the increasing prevalence of obstructive sleep apnea, low compliance & adherence towards CPAP, and rising awareness regarding sleep apnea, among other contributing factors.
 

The American population is becoming increasingly at risk due to the rise in cases of Obstructive Sleep Apnea (OSA). The American Lung Association believes that approximately 30 million adults over the age of 18 in the U.S. have OSA, out of which 80% are estimated to remain undiagnosed. Consequently, millions go untreated and undiagnosed, which is a rapidly emerging public health crisis. The rise in OSA cases has put a strain on the healthcare system due to the lack of effective treatment options, as existing therapies, like CPAP, are known to have extremely low adherence rates.
 

Due to the ability to provide long-term results without the need for nightly setup of treatment equipment, the popularity of sleep apnea implants is rapidly rising. Furthermore, the refinement of sleep apnea implant technology, due to the adoption of minimally invasive procedures, makes implants safer and more efficient. This is promising for the market and is taking it on a positive trajectory.   
 

Implants for sleep apnea refer to the surgical treatment of sleep apnea with particular medical apparatus or devices placed under the skin which aim to mechanically modify the obstructed airway, normalize the breathing process, and enhance oxygen delivery to the lungs.
 

U.S. Sleep Apnea Implants Market Trends

Technological developments in the U.S. has witnessed an increase in the use of sleep apnea implants. These new approaches encourage patients who are non-compliant with continuous positive airway pressure (CPAP) therapy. Enhancements have been made to create new treatment modalities, which are less invasive and more effective.
 

• An example of such is the Inspire Upper Airway Stimulation (UAS) system by Inspire Medical Systems. It is an implantable nerve stimulator that opens the airway by stimulating the hypoglossal nerve with small pulses of electrical energy.
   
• The device comes with an implantable pulse generator, externalizable parts including the physician programmer and patient remote, stimulation, and sensing leads.
   
• Recently, the FDA extended its criteria to include patients with an apnea hypopnea index (AHI) of 100 and 40 body mass index (BMI), which is expected to expand treatment access for a larger patient population.
   
• Technological advancements have enhanced the effectiveness of these apnea implants, driving their increased adoption in the U.S. market.
   

U.S. Sleep Apnea Implants Market Analysis

Based on product, the market is classified into hypoglossal neurostimulation devices and phrenic nerve stimulators. The hypoglossal neurostimulation devices segment generated the highest revenue of USD 770.7 million in 2024.
 

• Many patients with moderate to severe obstructive sleep apnea struggle to comply with CPAP therapies due to discomfort, noise, or other factors. New research from BMC Pulmonary Medicine has suggested that only 30% of OSA patients stick with CPAP therapy long term. In contrast, Hypoglossal neurostimulators are considerably less cumbersome than CPAPs, which improves acceptance in the primary market.
   
• In addition, there are multiple clinical studies on neurostimulation proving significant increase to oxygen saturation and AHI scores. For instance, in 2024, Science Direct reported that AHI was reducible by 20 events/hour with the Inspire device in the short term, and 16 events/hour in the long term.
   
• Cross-industry, regulatory agencies have been willing to support the advancement of HGNS devices. For instance, the FDA, in 2023, broadened the qualifying AHI range for these sleep apnea devices to include patients with an AHI of 15 - 100.
   
• This change now enables greater mild to moderate obstructive sleep apnea patients to pursue treatment, which has, in turn, fueled the market growth.
   

Based on indication, the U.S. sleep apnea implants market is classified into obstructive sleep apnea and central sleep apnea. The obstructive sleep apnea segment is expected to drive business growth and expand at a CAGR of 17.6%, reaching over USD 4 billion by 2034.
 

• Currently, obstructive sleep apnea (OSA) is estimated to affect 30 million Americans, many of whom remain undiagnosed. The American Academy of Sleep Medicine estimates that the economic impact of OSA contributes to unchecked losses of approximately USD 149.6 billion annually. In addition, untreated sleep apnea exacerbates existing negative health outcomes, spending an additional USD 30 billion every year on already existing comorbid conditions, healthcare, and medication. 
   
• Public awareness of the risks associated with untreated OSA (such as cardiovascular disease, diabetes, and cognitive decline) necessitates increased expenditures focused on OSA treatment. This places significant focus on effective treatment for patients who cannot tolerate CPAP therapy, highlighting the need for more implantable therapies.
   
• Hypoglossal nerve stimulation devices, an alternative to Continuous Positive Airway Pressure (CPAP) machines, are gaining further popularity. Even though CPAP is still the primary treatment for obstructive sleep apnea (OSA), a significant number of patients become non-compliant because of discomfort or treatment ineffectiveness. These implants provide a long-term, minimally invasive solution for moderate to severe OSA, making them an appealing option.

Based on end use, the U.S. sleep apnea implants market is segmented into hospitals and ambulatory surgical centers. The hospitals segment dominated the market with a revenue share of 60.7% in 2024.
 

• Implants provide long-term solutions to patients, especially those who do not tolerate CPAP therapy. Sleep apnea implants are phrenic nerve stimulators, hypoglossal nerve stimulators that require expert surgical intervention, which is best conducted in a hospital setting. Patients are optimally treated when diagnosed and managed in an inpatient setting. 
   
• In addition, patients have follow-up, postoperative adjustment, and monitoring requirements that are best met by hospitals. A number of varied hospitals cater to a diverse population with sleep disorder, and a portion are managed at advanced sleep medicine clinics. These clinics offer comprehensive care with polysomnography and respiratory therapy, along with device optimization, resulting in improved health outcomes. 
   
• These factors are leading to a projected substantial increase in the market for sleep apnea implants within the next few years.
   

U.S. Sleep Apnea Implants Market Share

In the U.S., the Inspire Medical Systems currently dominates the HGNS implants market holding a monopoly.  Overall, only two key players dominate the market through significant advancements in product innovation and strategic partnerships. These companies invest heavily in research and development to create advanced sleep apnea implants with enhanced safety features, user-friendly designs, and eco-friendly materials. They also establish partnerships with healthcare providers to improve product accessibility in emerging markets. Regulatory compliance and adherence to international quality standards are crucial to serving the market. These efforts help meet the growing demand for safe and effective sleep apnea implants.
 

U.S. Sleep Apnea Implants Market Companies

Prominent players operating in the U.S. sleep apnea implants industry include:

• Asahi KASEI
• Inspire

• Inspire – Inspire specializes in implantable devices that use hypoglossal nerve stimulation to keep airways open during sleep. This user-friendly, minimally invasive device is controlled by a handheld remote. Their innovative technology and commitment to patient comfort make Inspire a top choice, holding around 90% of the market share in the U.S. in the overall sleep apnea implant market.
   

U.S. Sleep Apnea Implants Industry News:

• In December 2023, the FDA approved the Inspire V therapy system by Inspire Medical Systems Inc. for treating moderate to severe obstructive sleep apnea (OSA). This advanced system includes an updated neurostimulator and Bluetooth-enabled patient remote and physician programmer, offering a more effective and patient-friendly solution. This approval is expected to enhance Inspire's market position and drive revenue growth by attracting a broader patient population seeking innovative and user-friendly treatment options.
   
• In April 2021, ZOLL Medical Corporation, an Asahi Kasei company, announced the acquisition of Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA). This acquisition expands ZOLL's critical-care portfolio, combining its expertise in cardiac and respiratory care with Respicardia's innovative remed? System, which is the only implantable device approved by the FDA to treat CSA in adult patients with reduced cardiac function.
   

The U.S. sleep apnea implants market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 — 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Hypoglossal neurostimulation devices
• Phrenic nerve stimulators

Market, By Indication

• Obstructive sleep apnea
• Central sleep apnea

Market, By End Use

• Hospitals
• Ambulatory surgical centers